Advertisement
Latest NewsBusiness

AstraZeneca's asthama drug fails in study

The drug failed to meet the goal of significantly reducing the annual asthama exacerbation rate in a late-stage study.

Latest News
AstraZeneca's asthama drug fails in study
Add DNA as a Preferred Source

Drugmaker AstraZeneca Plc said its asthma drug failed to meet the main goal of significantly reducing the annual asthma exacerbation rate in a late-stage study.

The drug, tralokinumab, failed against placebo, the company said, adding that it would now await the results from a second round of late-stage trial of the drug in the second half of the year.

Asthma affects about 315 million people worldwide, with about 10% suffering from severe asthma, the company said. 



REUTERSONLINE-NEWS

Find your daily dose of All Latest News including Sports News, Entertainment News, Lifestyle News, explainers & more. Stay updated, Stay informed- Follow DNA on WhatsApp.
Read More
Advertisement
Advertisement
Advertisement